Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer

SIMPLE SUMMARY: The mechanisms of intrinsic and acquired resistance to CDK4/6 inhibitors are poorly understood. Patients with HR+ MBC treated with CDK4/6i and antiestrogen therapy were grouped into early (<6 months), intermediate (6–24 months for 0–1 lines; 6–9 months for ≥2 lines), or late progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Sun, Yost, Susan E., Li, Sierra Min, Cui, Yujie, Frankel, Paul H., Yuan, Yate-Ching, Schmolze, Daniel, Egelston, Colt A., Guo, Weihua, Murga, Mireya, Chang, Helen, Bosserman, Linda, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264913/
https://www.ncbi.nlm.nih.gov/pubmed/35804935
http://dx.doi.org/10.3390/cancers14133159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264913/
https://www.ncbi.nlm.nih.gov/pubmed/35804935
http://dx.doi.org/10.3390/cancers14133159

Ejemplares similares